• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Amphetamine Extended Release Oral Suspension for ADHD

Amphetamine Extended Release Oral Suspension for ADHD

September 1, 2018
Rehan Aziz, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Rehan Aziz, MD. Dr. Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Childress AC et al, J Child Adolesc Psychopharmacol 2017;28(5):306–313

In 2015, the FDA approved Dyanavel XR (amphetamine extended release oral suspension), which was the first long-acting liquid version of amphetamine on the market. To provide some context, Quillivant XR, a long-action liquid methylphenidate formulation, was approved in 2012 and appears to be fairly popular for kids who can’t or won’t swallow pills. Seeing a market opportunity, Tris Pharmaceuticals developed Dyanavel XR and funded a placebo-controlled trial that was successful enough to gain FDA approval. Recently, this study was published, and some readers might be curious to look at the quality of the data.

The study took place at 5 investigational sites in the US. A total of 108 boys and girls with ADHD (ages 6–12) were initially enrolled in a 5-week open-label phase in which all patients were given Dyanavel XR, starting at 2.5–5 mg and titrated up to a target dose of 10–20 mg/day. Nine of the children dropped out of this first phase, and 99 continued on to the placebo-controlled phase of the study. Participants were randomly assigned to either Dyanavel XR (51 patients, mean dose 17.3 mg) or placebo (48 patients). After 1 week on the medication, the children’s ADHD symptoms were evaluated with a teacher-rated instrument called the SKAMP (for the Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale).

The primary outcome variable was improvement in SKAMP scores from pre-dose to post-dose of medication. Dyanavel XR was more effective than placebo beginning 1 hour after the dose and continuing for 13 hours. The effect size was a very robust 1.8, in line with effect sizes reported in similar trials of other long-acting stimulants. In terms of side effects, patients on Dyanavel XR reported decreased appetite (26%), insomnia (13%), and affect lability (9%), with no substantial differences in blood pressure or pulse between the treatment and control group.

CCPR’s take
Not too surprisingly, Dyanavel XR is an effective stimulant treatment for ADHD. This study was not huge but was well-designed, and the results were judged to be robust enough to merit FDA approval. It’s another arrow in our ever-expanding quiver of stimulant options, and this liquid formulation will likely be just as popular as Quillivant XR. Being a brand-name option, its cost is high. For families that want cheaper liquid stimulants, go with either generic ProCentra (short-acting dextroamphetamine) or Methylin oral solution (short-acting methylphenidate).
Child Psychiatry
KEYWORDS adhd research-update
    Rehan Aziz, MD.

    Medication Treatments for Alcohol and Opioid Use Disorder in Older Adults

    More from this author
    www.thecarlatreport.com
    Issue Date: September 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Depression in Children and Adolescents, CCPR, September/October 2018
    Amphetamine Extended Release Oral Suspension for ADHD
    Resilience Networks in Adolescent Females at Risk for Major Depression
    Note From the Editor-in-Chief
    Antidepressant-Induced Suicidality: What It Is and What You Should Do
    Current Use of Antidepressant Medication in Children
    Depression in Transition to Adulthood: A Case Study
    Bullying and Suicidality: Some Practical Tips
    CBT vs Pharmacotherapy for Childhood Anxiety
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.